Abstract | BACKGROUND: METHODS: RESULTS: Compared to the comparison group, the ACEI/ARB group [35.4% versus 39.3%; hazard ratio (HR), 0.84; 95% confidence interval (CI), 0.74-0.95] and CCB group (33.0% versus 41.9%; HR, 0.72; 95% CI, 0.64-0.81) had a lower risk of all-cause mortality during long-term follow up. The CCB group had a similar risk of all-cause mortality to the ACEI/ARB group. Risks of recurrent HS, ischemic stroke, or any stroke were not different between the study groups. CONCLUSIONS:
Antihypertensive drug class could be important to long-term outcomes in HS patients in addition to the target control of blood pressure. Both ACEIs/ARBs and CCBs are associated with lower risks of all-cause mortality. Our results may be applied to inform future research on hypertensive control in HS patients.
|
Authors | Chi-Hung Liu, Yu-Sheng Lin, Ching-Chi Chi, Chia-Wei Liou, Jiann-Der Lee, Tsung-I Peng, Tsong-Hai Lee |
Journal | Therapeutic advances in neurological disorders
(Ther Adv Neurol Disord)
Vol. 11
Pg. 1756286418802688
( 2018)
ISSN: 1756-2856 [Print] England |
PMID | 30283500
(Publication Type: Journal Article)
|